Cargando…

Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC

Over the last decade, the immune checkpoint blockade targeting the programmed death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis has improved progression-free and overall survival of advanced non-small cell lung cancer (NSCLC) patients. PD-L1 tumor expression, along with tumor mutational...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kloten, Vera, Lampignano, Rita, Krahn, Thomas, Schlange, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721635/ https://www.ncbi.nlm.nih.gov/pubmed/31374957 http://dx.doi.org/10.3390/cells8080809

Ejemplares similares

Multicenter Evaluation of Independent High-Throughput and RT-qPCR Technologies for the Development of Analytical Workflows for Circulating miRNA Analysis
por: Babayan, Anna, et al.
Publicado: (2020)

Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC
por: Chen, Jing, et al.
Publicado: (2021)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2019)

Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data
por: So, WeiQing Venus, et al.
Publicado: (2023)

Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC
por: Signorelli, Diego, et al.
Publicado: (2022)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker
por: Oualla, Karima, et al.
Publicado: (2021)

Circulating tumor cells PD‐L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non‐small‐cell lung cancer
por: Zhou, Qing, et al.
Publicado: (2023)

Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability
por: Tostes, Katiane, et al.
Publicado: (2023)

Immune checkpoint inhibitors alone vs immune checkpoint inhibitors—combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis
por: Wang, Yimin, et al.
Publicado: (2022)

Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
por: Zhang, Jie, et al.
Publicado: (2015)

Targeting YAP/TAZ in Combination with PD-L1 Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC)
por: Papavassiliou, Kostas A., et al.
Publicado: (2023)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
Publicado: (2021)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
por: Janning, Melanie, et al.
Publicado: (2019)

Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters
por: Castello, Angelo, et al.
Publicado: (2020)

Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients
por: Horesh, Adi, et al.
Publicado: (2023)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
por: Ma, Weijie, et al.
Publicado: (2016)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
Publicado: (2020)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
por: Tu, Megan M., et al.
Publicado: (2019)

Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC
por: Ishii, Hidenobu, et al.
Publicado: (2020)

Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis
por: Fitzsimmons, Timothy S., et al.
Publicado: (2023)

Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
por: Pandey, Pratibha, et al.
Publicado: (2022)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2020)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

ctDNA and CTCs in Liquid Biopsy – Current Status and Where We Need to Progress
por: Neumann, Martin H.D., et al.
Publicado: (2018)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022)

Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice
por: Garcia, Myrna G., et al.
Publicado: (2022)

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
por: Passiglia, Francesco, et al.
Publicado: (2016)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017)

Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
por: Sharma, Meenal, et al.
Publicado: (2019)

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
por: Masuda, Ken, et al.
Publicado: (2020)

Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC
por: Goh, Kah Yee, et al.
Publicado: (2023)

Biomarkers of therapeutic response with immune checkpoint inhibitors
por: Bindal, Poorva, et al.
Publicado: (2021)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers
por: Medjebar, Soleine, et al.
Publicado: (2020)

Real‐world data prognostic model of overall survival in patients with advanced NSCLC receiving anti‐PD‐1/PD‐L1 immune checkpoint inhibitors as second‐line monotherapy
por: Julian, Cristina, et al.
Publicado: (2022)

Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
por: Walia, Anushka, et al.
Publicado: (2023)

On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer
por: Correale, Pierpaolo, et al.
Publicado: (2020)

Atorvastatin Enhances the Efficacy of Immune Checkpoint Therapy and Suppresses the Cellular and Extracellular Vesicle PD-L1
por: Choe, Eun-Ji, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pfg5v338mc36vbev3j15gss3jb